Posted by Michael Wonder on 05 Jul 2024
Hinova Pharmaceuticals receives FDA fast track designation for HP518 for treatment of androgen receptor triple-negative breast cancer
5 July 2024 - Hinova Pharmaceuticals today announced that the US FDA has granted fast track designation for HP518, an investigational drug for the treatment of androgen receptor positive triple-negative breast cancer.
HP518 is a potent PROTAC androgen receptor degrader showing efficacy in androgen receptor positive triple-negative breast cancer.
